Jové Mireia, Planavila Anna, Laguna Juan Carlos, Vázquez-Carrera Manuel
Pharmacology Unit, Department of Pharmacology and Therapeutic Chemistry, University of Barcelona, E-08028 Barcelona, Spain.
Endocrinology. 2005 Jul;146(7):3087-95. doi: 10.1210/en.2004-1560. Epub 2005 Mar 31.
The mechanisms by which elevated levels of free fatty acids cause insulin resistance are not well understood. In addition, accumulating evidence suggests a link between inflammation and type 2 diabetes. Here, we report that exposure of C2C12 skeletal muscle cells to 0.5 mm palmitate results in increased mRNA levels (3.5-fold induction; P < 0.05) and secretion (control 375 +/- 57 vs. palmitate 1129 +/- 177 pg/ml; P < 0.001) of the proinflammatory cytokine IL-6. Palmitate increased nuclear factor-kappaB activation and coincubation of the cells with palmitate and the nuclear factor-kappaB inhibitor pyrrolidine dithiocarbamate prevented both IL-6 expression and secretion. Furthermore, incubation of palmitate-treated cells with calphostin C, a strong and specific inhibitor of protein kinase C, and phorbol myristate acetate, that down-regulates protein kinase C in long-term incubations, abolished induction of IL-6 production. Finally, exposure of skeletal muscle cells to palmitate caused a fall in the mRNA levels of glucose transporter 4 and insulin-stimulated glucose uptake, whereas in the presence of anti-IL-6 antibody, which neutralizes the biological activity of mouse IL-6 in cell culture, these reductions were prevented. These findings suggest that IL-6 may mediate several of the prodiabetic effects of palmitate.
游离脂肪酸水平升高导致胰岛素抵抗的机制尚未完全明确。此外,越来越多的证据表明炎症与2型糖尿病之间存在联系。在此,我们报告,将C2C12骨骼肌细胞暴露于0.5 mM棕榈酸酯会导致促炎细胞因子IL-6的mRNA水平升高(诱导3.5倍;P < 0.05)和分泌增加(对照组375 ± 57 vs. 棕榈酸酯组1129 ± 177 pg/ml;P < 0.001)。棕榈酸酯增加了核因子-κB的激活,将细胞与棕榈酸酯和核因子-κB抑制剂吡咯烷二硫代氨基甲酸盐共同孵育可阻止IL-6的表达和分泌。此外,用强效且特异性的蛋白激酶C抑制剂钙泊三醇C以及在长期孵育中下调蛋白激酶C的佛波酯肉豆蔻酸酯孵育经棕榈酸酯处理的细胞,可消除IL-6产生的诱导。最后,将骨骼肌细胞暴露于棕榈酸酯会导致葡萄糖转运蛋白4的mRNA水平下降以及胰岛素刺激的葡萄糖摄取减少,而在存在中和细胞培养中小鼠IL-6生物活性的抗IL-6抗体的情况下,这些减少被阻止。这些发现表明IL-6可能介导了棕榈酸酯的几种糖尿病前期效应